The COVID-19 Saliva-based Screening Market to sizzle at a CAGR of -3% between 2022-2031
The global COVID-19 saliva-based screening market was valued at over US$ 1.7 Bn in 2020, and is expected to exhibit a declining CAGR of -3% between 2022-2031.
Stay updated with breaking news from Chembio Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The global COVID-19 saliva-based screening market was valued at over US$ 1.7 Bn in 2020, and is expected to exhibit a declining CAGR of -3% between 2022-2031.
Dublin, April 22, 2022 (GLOBE NEWSWIRE) -- The "Global Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease (HIV,...
/PRNewswire/ -- The "Global Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease (HIV, Hepatitis C), Pregnancy Test), Platform...
/PRNewswire/ -- The "Global Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease (HIV, Hepatitis C), Pregnancy Test), Platform...
/PRNewswire/ -- The global rapid diagnostics market size is expected to increase by USD 12.74 billion between 2021 and 2026, expanding at a CAGR of 7.58%...